AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

American Journal of Public Health, Vol. 85, Issue 6 843-845, Copyright © 1995 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jackson, L A
Right arrow Articles by Wenger, J D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackson, L A
Right arrow Articles by Wenger, J D
Should college students be vaccinated against meningococcal disease? A cost-benefit analysis.

L A Jackson, A Schuchat, R D Gorsky and J D Wenger

National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga 30333, USA.

Outbreaks and sporadic cases of meningococcal disease among college students have prompted consideration of a policy of routine vaccination for this group. Purchase and administration of the vaccine for routine vaccination would cost $56 million per year. Savings in medical care and indirect costs would not equal this amount unless the annual rate of disease among students is at least 6.5/100,000. The actual rate among students is unknown; however, surveillance data suggest it could not be more than 1.3/100,000. At rates near this estimate, the net cost of the program would be approximately $45 million annually. More cost-effective prevention strategies might be yielded by further studies to identify students at substantial risk of meningococcal disease, or by the development of a conjugate serogroup C vaccine that could be administered during infancy.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
L. H. Harrison
Prospects for Vaccine Prevention of Meningococcal Infection
Clin. Microbiol. Rev., January 1, 2006; 19(1): 142 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
K. R Neal, J. S Nguyen-Van-Tam, N. Jeffrey, R. C B Slack, R. J Madeley, K. Ait-Tahar, K. Job, M. C J Wale, and D. A A Ala'Aldeen
Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study
BMJ, March 25, 2000; 320(7238): 846 - 849.
[Abstract] [Full Text]

Home page
 JAMAHome page
L. H. Harrison, D. M. Dwyer, C. T. Maples, and L. Billmann
Risk of Meningococcal Infection in College Students
JAMA, May 26, 1999; 281(20): 1906 - 1910.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
K. A. Moore and M. T. Osterholm
Meningococcal Disease and Public Health Practice: A Complicated Road Map
JAMA, February 11, 1998; 279(6): 472 - 473.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Public Health Association